Endocrine Abstracts

A 61-year-old male was referred for hypercalcaemia. He was experiencing generalized fatigue and underwent several investigations which included serum calcium. He had recently been treated for two episodes of chest infections. At that time, he was also experiencing weight loss and night sweats. His symptoms have since resolved. He had no symptoms of hypercalcaemia- polyuria, polydipsia, abdominal pain, constipation, bone pain, or headaches. He was not taking calcium supplements...

Background: Whether metformin might affect the risk of benign nodular goiter in patients with type 2 diabetes mellitus has not been investigated.Methods: Patients with new-onset type 2 diabetes mellitus during 1999-2005 were enrolled from Taiwan’s National Health Insurance database. Analyses were conducted in a propensity score matched-pairs of 20,048 ever users and 20,048 never users of metformin. The patients were followed until December 31, 2011 ...

Purpose: To determine the proportion of abnormal current perception threshold (CPT) in patients with type 2 diabetes mellitus.Methods: A total of 1360 patients with type 2 diabetes mellitus involved in an epidemiological study received an examination of CPT measured by Neurometer® CPT/C (Neurotron, Inc., Baltimore, Maryland, USA) on a supine position. The measurement was taken for three frequencies, i.e., 5, 250 and 2000 Hz at three sites: the preau...

Background: Whether sitagliptin may affect oral cancer risk has not been investigated.Methods: The reimbursement database of the National Health Insurance in Taiwan was used. Diabetic patients newly treated with sitagliptin (n=50033) or other antidiabetic drugs (n=277038) within 1999–2008 were followed for oral cancer until December 31, 2011. The treatment effect was estimated by Cox regression adjusted for propensity score (PS) or...

Background: Whether sitagliptin use in patients with type 2 diabetes mellitus may affect the risk of thyroid cancer requires further investigated.Methods: The reimbursement database of the National Health Insurance in Taiwan was used. Patients with newly diagnosed type 2 diabetes mellitus within 1999–2008 were recruited and followed for at least 6 months for thyroid cancer until December 31, 2011. Patients were divided into those who were newly trea...

Background: Whether metformin therapy affects bladder cancer risk in patients with type 2 diabetes mellitus (T2DM) has not been extensively investigated.Methods: The reimbursement databases of all Taiwanese patients with a new diagnosis of T2DM between 1998 and 2002 (n=940708) were retrieved from the National Health Insurance for follow-up of bladder cancer up to the end of 2009. Of these patients, 532519 were never-users and 408189 were ever-us...

The mammalian corpus luteum secretes progesterone under the influence of luteinizing hormone (LH). LH acts by binding to its G-protein coupled receptor and elevating intracellular cAMP thus activating protein kinase A (PKA). However, the exact role of PKA in the regulation of progesterone secretion remains unelucidated. Thus in this study we have investigated the relationship between PKA expression/activity and progesterone secretion during luteinization. Human granulosa cells...

Introduction: Treatment-induced neuropathy of diabetes (TIND) is a small fibre neuropathy precipitated by rapid correction of chronic hyperglycemia. Methods: We report two patients who developed TIND after rapid improvement of glycaemic control. Results: 21-year-old gentleman, underlying type 2 DM diagnosed since 2017. He was not compliant to insulin therapy and defaulted follow up. His Hba1c ranged from 16.6%-19%. In July 2020, he...

Objective: Generously supported by IPSEN)-->The relationship between the paradoxical response of GH secretion after thyrotropin-releasing hormone (TRH) administration and tumor size has been the subject of only a few studies with conflicting results.Design: The aim of this study was to investigate how the paradoxical response of GH secretion to TRH changes according to tumor size.Methods:...

Several recent studies have shown that early intensive insulin therapy can improve β-cell function in newly diagnosed type 2 diabetes. However, in clinical practice, insulin therapy has not been widely used in out-patients due to the fact that insulin therapy is perceived by the patients as the strongest and the last remedy and patients fear that, once on that therapy, they will have to remain on it for life. In fact, based on our clinical data, out-patients, who were new...